Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors

J Med Chem. 1996 Feb 2;39(3):802-6. doi: 10.1021/jm950518r.

Abstract

A series of adenosine-5'-uronamide derivatives bearing N6-phenylurea groups have been synthesized and tested for their affinity at A1 and A2A adenosine receptors in rat brain membranes and at cloned rat A3 receptors from stably transfected CHO cells. Some N6-arylcarbamoyl derivatives, N6-((2-chlorophenyl)carbamoyl)-, N6-((3-chlorophenyl)carbamoyl)-, and N6-((4-methoxyphenyl)carbamoyl)adenosine-5'-ethyluronamide (4l-n), were found to have affinity at A3 receptors in the low nanomolar range (Ki values < 10 nM). In CHO cells stably transfected with the rat A3 receptor, compound 4n was found to be a full agonist in inhibiting adenylate cyclase activity. The present study represents the first example of N6-acyl-substituted adenosine analogs having high affinity at adenosine receptors and, in particular, at the A3 receptor subtype.

MeSH terms

  • Adenylyl Cyclases / metabolism
  • Amides / metabolism
  • Amides / pharmacology*
  • Animals
  • Brain / drug effects
  • Brain / metabolism
  • CHO Cells
  • Cricetinae
  • Male
  • Purinergic P1 Receptor Agonists*
  • Rats
  • Rats, Sprague-Dawley

Substances

  • Amides
  • Purinergic P1 Receptor Agonists
  • Adenylyl Cyclases